tiprankstipranks

CymaBay downgraded to Market Perform from Outperform at LifeSci Capital

LifeSci Capital analyst Cory Jubinville downgraded CymaBay (CBAY) to Market Perform from Outperform with a $32.50 price target after Gilead Sciences (GILD) announced an agreement to acquire Cymabay for $32.50 per share in cash.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on CBAY:

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue